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Abstract: The specific pathogenesis underlying inflammatory bowel disease is complex, and it 
is even more difficult to decipher the pathophysiology to explain for the similarities and differ-
ences between two of its major subtypes, Crohn’s disease and ulcerative colitis (UC). Animal 
models are indispensable to pry into mechanistic details that will facilitate better preclinical 
drug/therapy design to target specific components involved in the disease pathogenesis. This 
review focuses on common animal models that are particularly useful for the study of UC and 
its therapeutic strategy. Recent reports of the latest compounds, therapeutic strategies, and 
approaches tested on UC animal models are also discussed.
Keywords: inflammatory bowel disease, preclinical trials, emerging therapy
Introduction to ulcerative colitis
Ulcerative colitis (UC) is an idiopathic chronic relapsing–remitting inflammatory 
disorder that affects the colon, characterized by diarrhea and rectal bleeding (Figure 1). 
The molecular etiology of UC development is complex and involves genetic, microbial, 
environmental, and other unknown factors (Figure 1). In this review, we discuss the 
underlying pathophysiology of UC and how observations from animal models that 
mimic UC contribute to better understanding of this disease and lead to advancement 
in novel treatment design.
Based on recent reports, there is a steady increase in the global incidence of UC. 
Currently, the prevalence in Europe and North America is 24.3 and 19.2 per 100,000 
individuals, respectively, and 6.3 per 100,000 people in Asia and the Middle East.1 
Most patients develop UC between the ages of 15 and 30 years, although individuals 
aged 50–70 years form another potential risk group.2 There are no significant differ-
ences in UC risk between sexes. The growing prevalence of this disease increases both 
economic and health care burdens. In the United States, an individual UC patient has 
an average annual expenditure of approximately $15,020 in medical costs.3 Thus, better 
and more affordable treatments and eventually a cure are greatly needed.
An individual’s genetic makeup forms one of the primary causal factors for inflam-
matory bowel disease (IBD) development. The first clue that there is a partial genetic 
component to the risk of IBD comes from the observation that a family history of 
IBD confers one with a higher probability of disease development. The offspring of 
IBD-affected mothers have a higher incidence of developing the disease as compared 
with the offspring of IBD-affected fathers, indicating that maternal inheritance factors 
predetermine UC-related genetic risk.4 Molecular studies have also shown evidence of 
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UC-associated genetic imprinting, such that maternal inher-
ited gene expression and functions have been directly linked 
to IBD development.5 Recent Genome-Wide Association 
Studies have also identified 47 UC risk alleles.6 In addition 
to direct DNA sequence variants, changes in epigenetics, 
including DNA methylation, histone modifications, and 
noncoding RNA, contribute an additional layer of genetic 
contribution to IBD risk.
Environment and lifestyle constitute the second major 
arm of UC causal factors. During infancy, early exposure 
to microbes protects individuals from UC development at 
subsequent life stages. This is in sync with the notion that 
improved sanitation in developed countries may lead to 
immaturity of an individual’s immune system during child-
hood and subsequently increase susceptibility to UC later in 
life. Seasonal changes also exacerbate UC conditions, such 
that symptoms occur more frequently during spring and sum-
mer seasons.7 Meta-analysis has shown that smokers tend 
to be protected from UC as compared with nonsmokers.8 In 
contrast to UC, smoking appears to worsen Crohn’s disease 
(CD) symptoms.9
With the identification of these fundamental causal fac-
tors, the next step is to prioritize the directions for the next 
wave of UC research. The Crohn’s and Colitis Foundation of 
America composed a list of priorities for IBD research agen-
das, with the ultimate goal of applying bench-side discoveries 
to the bedside.10 To facilitate understanding of UC patho-
genesis, animal models, particularly mouse models, have 
become indispensable tools to study this topic (Figure 2). 
Experimental colitis can be induced using chemical irritant 
or bacterial infection. Over the years, many transgenic (Tg) 
and gene knockout (KO) mouse strains have been developed, 
allowing the opportunity to address specific pathophysiologic 
questions related to UC and to test novel drug/therapeutic 
candidates pertinent to specific components/pathways.
Chemical and bacterial induction  
of colitis in animal models
A UC-like phenotype can be induced in animals easily 
using either chemical administration or bacterial infection. 
Although the majority of these reports were performed on 
mice, chemically induced colitis has also been tested on other 
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Ulcerative colitis
Figure 1 Clinical and histological features of ulcerative colitis (UC) and causal factors influencing UC risk. Common diagnostic criteria of UC include both clinical and 
histological features. The main causes of UC are individual genetic background as well as environmental factors, which may alter/synergize with the genetic/epigenetic 
makeup.
Abbreviations: UC, ulcerative colitis; NSAID, nonsteroidal anti-inflammatory drug.
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species, ranging from lower organisms such as zebrafish and 
drosophila to higher organisms, including rats and porcine. 
The choice of animal and induction method will depend on 
the specific question the particular study is addressing.
Dextran sulfate sodium-induced colitis
A common method to create ulcer formation and inflam-
mation is through administration of dextran sulfate sodium 
(DSS) to animals. Strictly speaking, DSS does not directly 
cause intestinal inflammation per se; rather, it exerts chemical 
injury to the intestinal epithelium, resulting in exposure of the 
lamina propria (LP) and submucosal compartment to luminal 
antigens and enteric bacteria, triggering inflammation. The 
effectiveness of DSS-induced colitis depends on several 
factors, including dosage (usually 1%–5%), duration (acute 
or chronic), manufacturer/batch of DSS, strain of animals 
(C3H/HeJ and Balb/c mice strains are more susceptible), sex 
of animals (male mice are more susceptible), and microbial 
environment of animals (eg, germ-free [GF] versus specific 
pathogen-free [SPF]). In addition, DSS-administered mice 
also show highly variable disease severity. Unless animals 
are treated with multiple pulses of DSS, the phenotype lacks 
the chronic changes observed in humans. Nevertheless, DSS-
induced colitis is still commonly used, given its simplicity 
to administer (usually in the drinking water) and the ease of 
controlling the dosage (to determine severity) and duration 
(to study the inflammatory or recovery process). Although the 
earliest change in this model is characterized by a progres-
sive disruption of colonic crypts, macrophages and cluster 
of differentiation 4 (CD4+) T cells become more prominent 
in areas of wound healing in the basal portion of the LP after 
the late recovery phase.11 Many chemical compounds, gene/
cell therapy, and microbial interventions have been reported 
to be therapeutically effective in DSS-induced colitis (see 
review by Mizoguchi12).
Oxazolone colitis
Intrarectal administration of the hapten oxazolone with etha-
nol into murine animals results in acute colitis. The condition 
is characterized by a T helper (Th)2-type immune response 
with a marked increase in interleukin (IL)-4 and IL-5 pro-
duction, accompanied by body weight loss, diarrhea, ulcers, 
and loss of epithelial cells in the large intestine.13 Thus, it 
resembles UC rather than other IBD subtypes, distinguish-
ing it from trinitrobenzene sulfonic acid (TNBS)-induced 
colitis (Th1-mediated immune responses), which mimics 
CD more closely. Natural killer T cells and their associated 
cytokine, mainly IL-13, are also intimately involved in 
oxazolone-induced colitis induction.14 Many studies have 
utilized oxazolone-induced colitis to test disease pathology 
and therapeutic interventions for UC.15,16 It was recently 
shown in oxazolone-treated mice that nicotine upregulates 
CD UC
Transgene/knockout Transgene/knockout
Mouse IBD models
Chemical Chemical
TNBS
Indomethacin
DSS
TNBS (Balb/c)
Oxazolone
Acetic acid
Sulfhydryl inhibitors
SAMP1/YitFc
N-cadherin dominant negative mutant
TNF∆ARE
TCRα−/−
WASP−/−
Mdr1a−/−
IL-2−/−
Gαi2−/−
IL-7 Tg
Adoptive transfer
TRUC (Tbet−/−XRag2−/−)
TGFβRIIDN
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Figure 2 Mouse models of inflammatory bowel disease (IBD). Many mouse models are currently available that mimic the two major subtypes of IBD (Crohn’s disease [CD] 
and ulcerative colitis [UC]). Specific mouse models with characteristics of CD and/or UC are summarized. 
Abbreviations: ΔARE, a deletion nutant in AU-rich elements; DSS, dextran sulfate sodium; Gαi2, guanine nucleotide-binding protein G(i) subunit α-2; iL, interleukin; 
Mdr1a, multiple drug resistance 1a; TCR, T-cell receptor; Tg, transgenic; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TNF, tumor necrosis factor; TRUC, T-bet(−/−)RAG2(−/−) 
ulcerative colitis; wASP, wiskott–Aldrich syndrome protein; TGF, transforming growth factor.
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the nicotine acetylcholine receptors on CD4+ T cells and 
increases regulatory T cell (Treg) numbers, accompanied 
by a decrease in the number of Th17 cells, resulting in the 
amelioration of the inflammatory phenotype.16 In contrast, 
nicotine treatment in TNBS-induced mice, which have 
CD-like Th1-associated inflammation, upregulates Th17 
cell numbers associated with an exacerbation of the inflam-
matory response. In a separate study, mice treated with 
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor 
showed suppression of the Th1 response and attenuation of 
intestinal inflammation in TNBS-induced colitis, but not 
oxazolone-induced colitis.15 These examples illustrate the 
importance of choosing an appropriate model to answer a 
specific question when exploring a therapeutic potential of 
a drug/compound for a particular disease.
Acetic acid-induced colitis
Intrarectal administration of diluted acetic acid provides an 
alternative method to create chemical injury to the mucosal 
epithelium that induces a transient phenotype mimicking 
UC. The first report of this model was demonstrated by 
MacPherson and Pfeiffer17 where they instilled 10%–50% 
acetic acid into the rat rectum for 10 seconds, followed by 
flushing the lumen with saline three times. A diffuse colitis 
in an acetic acid dose-dependent manner was observed in 
these rats, with histopathological features including ulcer-
ation of the distal colon and crypt abnormalities.17 The 
ulcerated and injured mucosa, with destruction sometimes 
extending to the LP, begins to heal within days in mice and 
a few weeks later in rats.18 Subsequent modifications and 
optimization over years focused on varying the concentra-
tion of acetic acid and the contact time. As enemas of high 
concentration of acetic acid into the lumen often cause 
perforations, the latest protocol is executed using 4% acetic 
acid with 15–30 seconds of exposure. The advantages of 
acetic acid-induced colitis are its low cost and the ease of 
administration.
There are a large number of reports that describe com-
pounds that can ameliorate acetic acid-induced colitis. These 
include compounds aiming to target reactive oxidative spe-
cies such as N-acetyl cysteine, trimetazidine, vitamin E, and 
melatonin, suggesting that acetic acid-induced colitis may 
be a good model to study the efficacy of drugs that aim to 
interfere with reactive oxidative species pathogenesis.19–22 Of 
note, the epithelial injury observed within the first 24 hours 
of acetic acid induction is not immunologic in nature. Thus, 
designing drugs that target immune responses should be 
tested at a time point after 24 hours postinduction.
Salmonella-induced colitis
The gram-negative Salmonella typhimurium and Salmonella 
dublin are food-borne enteric bacterial pathogens that 
can cause intestinal diseases. Direct oral infection of 
S. typhimurium into mice results in systemic infection that 
may mask the phenotype of intestinal inflammation. However, 
this problem can be overcome by pretreating mice with an 
oral antibiotic cocktail to disrupt commensal microbial flora 
and allow better colonization of S. typhimurium, resulting in 
high-density growth of the bacterium within a day. The initial 
inflammation caused by such colonization has similar histo-
pathological characteristics to human UC, including epithelial 
crypt loss, erosion, and neutrophilic infiltration. Of note, this 
mode of colitis induction usually results in systemic infection 
within 5–7 days of infection. Therefore, it is perceived that 
S. typhimurium infection is a valuable model to study the 
acute phase, but not later stages, of colitis.
Salmonella has been shown to function as a good vector 
to introduce certain gene components into the mucosa to 
elicit immune response for vaccines against colitis.23 It can 
efficiently invade into the intestinal epithelium and Peyer’s 
patches (PP). Therefore, careful and detailed characteriza-
tion of its virulence factors is critical to efficiently create 
a safe attenuated strain for such gene therapy vaccination. 
Vaccinating mice with an attenuated mutant S. typhimurium 
strain that contains deletion of the znuABC operon, which 
encodes a zinc importer responsible for metal recruitment 
in the infected host, elicits effective immune responses and 
protects mice from subsequent Salmonella infection.23 In 
addition, elucidating how S. typhimurium interacts with 
host epithelial cells facilitates further understanding of 
ways to potentially prevent UC onset. For instance, blocking 
host inflammatory-induced proteins (eg, chitinase 3-like 1 
[CHI3L1, also known as YKL-40]) in the colon using appro-
priate antibodies (Abs) or inhibitors can prevent colonization 
of S. typhimurium on the intestinal epithelium, thus prevent-
ing further invasion.24
Adherent–invasive E. coli
The commensal adherent–invasive Escherichia coli (AIEC) 
strain was originally isolated from the ileum of CD patients 
and was shown to exacerbate intestinal inflammation in an 
opportunistic manner.25 However, AIEC can adhere to both 
small and large intestinal epithelial cells (IECs) with equal 
affinity.26 Induction of colonic inflammation in animal mod-
els using AIEC infection requires mild epithelial damage, 
such as low-dose DSS treatment, during the entire course 
of the infection. The phenotype of the colonic inflammation 
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mimics UC, including body weight loss, presence of blood in 
stool, and colonic neutrophilic infiltrations.24 A recent study 
showed that AIEC encodes a pathogenic form of chitinase, 
chiA, that is distinguishable from other nonpathogenic E. coli 
and is utilized to adhere to host epithelial cells by binding 
with colonic inducible protein CHI3L1.27 Administration of 
chitin microparticles (1–10 µm in size) into mice ameliorates 
colonic intestinal inflammation, presumably by blocking the 
interaction of bacterial-derived factors (such as AIEC chiA) 
with host CHI3L1.28 Similarly, using anti-CHI3L1 Abs also 
resulted in an ameliorative effect.24
Effective invasion into, and colonization of, AIEC in the 
mucosal epithelium is usually hindered by mucosal biofilm 
formation of probiotic bacteria, such as Lactobacillus casei.29 
Certain antibiotics result in the disruption of the intestinal 
microflora, including the probiotic biofilm, creating an ideal 
environment for the opportunistic AIEC to adhere to and 
invade IECs and macrophages. It has been shown that AIEC 
does not adhere efficiently in non-antibiotic-treated mice, 
but colonizes well in the antibiotic-treated animals.30 This 
result suggests that restoration of a beneficial microbiota, 
either through probiotic intake or other methods such as 
fecal microbial transplantation, can theoretically prevent 
further exacerbation of intestinal inflammation by commensal 
pathogenic bacteria.
Transgenic and gene knockout 
animal models of ulcerative colitis
IL-7 Tg mice
IL-7 is a pleiotropic cytokine and a candidate risk gene 
associated with UC. IECs express IL-7, which serves as a 
regulatory factor for the development and homeostasis of 
lymphocytes that express IL-7 receptor (IL-7R).31 In UC 
patients, IL-7 protein expression is significantly upregulated 
and exerts its optimal effects in maintaining long-lived 
memory CD4+ T cells in colonic mucosa.32 IL-7 appears to 
mediate the persistence of chronic colitis through the IL-7Rα 
chain expressed specifically on CD4+ T cells, but not on other 
cell types.33 Thus, blocking IL-7R functions has shown to be 
effective in suppressing adoptive transfer-induced intestinal 
inflammation in mice.34 Administration of specific anti-IL-7R 
Ab into murine colitis models (eg, Helicobacter bilis-infected 
Mdr1 KO mice) also controls macrophage and dendritic cell 
(DC) expansion.35
IL-7 Tg mice expressing the murine IL-7 complementary 
DNA spontaneously develop acute colitis at 1–3 weeks of age, 
characterized by a mixed cellular infiltration that includes 
neutrophils and lymphocytes.36 At 8–12 weeks of age, the Tg 
mice display rectal prolapse and remittent intestinal bleeding, 
with rectal erosion, goblet cell loss, and occasional crypt 
abscesses. Upregulation of IL-7R on mucosal lymphocytes 
is also associated with disease progression.36 Thus, an IL-7 
Tg mouse model is useful to understand T-cell-mediated 
pathogenesis of colitis for therapeutic interventions targeting 
T-cell functions.
TCRα KO mice
In 1993, Mombaerts et al37 showed that T-cell receptor α 
chain (TCRα) KO mice spontaneously developed chronic 
colitis, which was mediated by a Th2-type immune response 
closely resembling human UC with an inflammatory pattern 
restricted primarily to the colonic mucosa. At 4–6 months 
of age, approximately 60% of TCRα KO mice produced 
soft stools, associated with loss of goblet cells, and a mixed 
cellular infiltration mainly consisting of lymphocytes and 
neutrophils in the affected LP. Spontaneous colitis develops 
in TCRα KO animals when raised in a helicobacter-free/SPF 
facility, but not in GF or conventional (CV) environments.38 
When SPF-born TCRα KO mice were subsequently trans-
ferred into a CV environment, the mice developed attenuated 
mild colitis.39 This supports the notion that early life exposure 
to environmental microbes may be protective against colitis 
risk later in life.
Several therapeutic interventions have been tested 
in TCRα KO mice with efficacy. Daily oral administration 
of 3 mg/kg dexamethasone, a member of the glucocorticoid 
class of steroid drugs, into TCRα KO mice was effective 
in preventing goblet cell loss and leukocyte infiltration.40 
Immunotherapy treatment using anti-IL-4 Abs has also 
been shown to suppress both clinical and histological signs 
of colitis by controlling Th2-type cytokine productions.41 
Administration of purified immunoglobulin G, with a 
mixture of monoclonal auto-Abs reactive against colonic 
epithelial cells, can attenuate colitis in B-cell-deficient 
TCRα KO mice.42 Carbon monoxide, a prominent compo-
nent in cigarette smoking, exerts anti-inflammatory effects 
in TCRα KO mice through suppression of IL-1β, tumor 
necrosis factor-α (TNFα) and IL-4, as well as through 
induction of IL-10 production, providing molecular 
insights into how smoking has protections against UC.43 In 
addition, oral administration of chitin microparticles into 
TCRα KO colitic mice also showed suppression of IL-4 
and TNFα production and increased interferon-γ (IFNγ) 
production in the mesenteric lymph nodes (MLNs).28 It 
was found that chitin treatment in TCRα KO mice normal-
izes intestinal bacterial composition, as compared with 
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control groups that exhibit expansion of a certain genre 
of commensals microbes.
wiskott–Aldrich syndrome  
protein KO mice
Patients with Wiskott–Aldrich syndrome have not only 
immunodeficiency but also often autoimmune manifes-
tations, with 5%–10% of patients developing colonic 
inflammation.44,45 They either lack or express a defective 
form of Wiskott–Aldrich syndrome protein (WASP), an 
intracellular molecule specific to hematopoietic cells. Given 
the major biological role of WASP in actin polymerization, it 
is crucial for multiple cellular functions such as cell motility, 
activation, and signaling.46 Like their human counterpart, 
WASP KO mice on the 129 SvEv background also develop 
spontaneous colitis from 4 months of age. Full penetrance 
was observed at 6 months of age. The pancolitic pattern of 
inflammation along with elevations in Th2 cytokines in the 
colonic LP associated with this model mirror features of 
UC.47 Initially, it was hypothesized that aberrantly activated 
effector T cells as well as deficient and dysfunctional Tregs 
associated with WASP deficiency bore the sole responsibil-
ity for colitis development, but more recent studies have 
revealed a role of WASP KO innate immune cells in disrupt-
ing mucosal regulation.47,48 The advantages of using this 
model for studying UC pathogenesis are the Th2-skewed 
cytokine profile mimicking human disease, aberrant natural 
Treg and innate immune cell function, and a human correlate 
where a subset of patients with the same genetic defect also 
suffer from colitis.
Several treatment strategies have been investigated using 
WASP KO animals. WASP-expressing retrovirus was trans-
duced into WASP-deficient hematopoietic stem cells before 
transfer into lethally irradiated recipient mice, resulting in the 
attenuation of colitis along with normalized populations of 
mature B and T cells compared with chimeric mice with con-
trol retrovirus-transduced WASP-deficient bone marrow cells 
that developed disease.49 In addition, given that UC patients 
were found to produce lower levels of intestinal alkaline 
phosphatase, WASP KO mice were treated with oral intestinal 
alkaline phosphatase and were found to effectively attenuate 
colitis with less cellular infiltration and reduced production of 
IL-4 and IFNγ.50,51 Furthermore, direct neutralization of IL-4, 
but not IFNγ, with weekly injection of anti-IL-4 antibody 
for 8 weeks ameliorated disease.47 Lastly, administration of 
a newly formulated IL-10-immunoglobulin fusion protein 
completely abrogated colitis development in chimeric mice 
with WASP-deficient innate immune cells.48
Mdr1a KO mice
Mdr1a KO mice lack the multiple drug resistance 1a (mdr1a) 
gene, encoding for the cell surface P-glycoprotein (P-gp) 
transporter that pumps small amphiphilic/hydrophobic 
molecules across the cell membrane. Approximately 25% 
of these mice develop colitis between 8 and 36 weeks of 
age when raised in an SPF facility, but not in a GF facility.52 
Histological findings in this model include mucosal thicken-
ing and loss of goblet cells that is also accompanied by crypt 
abscesses and ulceration in the colon.52 Mdr1a KO mice are 
devoid of the proper ability to dispose of bacterial breakdown 
products in epithelial cells. The accumulation of these bacte-
rial products increases excess/abnormal antigen presentation 
to neighboring T cells, leading to a marked T-cell activation 
state that drives the colitis. Recently, T-cell involvement 
in the development of colitis in the Mdr1a KO model has 
been increasingly characterized. The lack of Mdr1a (P-gp) 
restricts the development of inducible Treg cells, thus pro-
ducing fewer functional forkhead box P3 (Foxp3)-positive 
Treg cells and therefore less IL-10 production to control and 
regulate intestinal inflammation.53 Hematopoietic-specific 
Mdr1a deficiency results in a more severe colitis than mice 
that have Mdr1a deficiency only in IECs, suggesting a critical 
role of immune cell-derived P-gp in colitis development.54
Consistent with the finding that Mdr1a KO mice in a GF 
facility do not develop colitis, prophylactic treatment using 
broad-spectrum oral antibiotics greatly reduces the incidence 
of colitis development.52 Mdr1a KO mice fed with a diet con-
taining a polyphenol compound called curcumin (commonly 
found in spices used in Asian food) demonstrated upregula-
tion of xenobiotic metabolism as well as downregulation 
of proinflammatory pathways and associated attenuation 
of histological signs of colitis.55 Meta-analysis has identi-
fied several polymorphisms in the Mdr1a locus in human 
UC, but not CD, patients that affect its gene expression and 
regulation.56 Loss of Mdr1a expression was implicated in 
UC development, but not in CD patients.57 Administration 
of the probiotics Lactobacilli upregulates P-gp expression 
under both normal and inflammatory conditions, and reduces 
myeloperoxidase activity and histological signs of injury in 
DSS-treated mice.58 These results suggest that Mdr1a KO 
mice can be utilized in the design of drugs targeting intestinal 
epithelial barrier dysfunction and in elucidating the mecha-
nisms underlying the benefits of probiotic treatment.
iL-2 KO mice
IL-2 is an effective regulatory cytokine produced by CD4+ 
T cells and amplifies stimulatory responses by promoting 
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T lymphocyte expansion. IL-2 KO mice are viable and 
develop normally before 4 weeks of age, thereafter displaying 
50% mortality. The remaining mice develop colon-restricted 
inflammation with 100% penetrance by 6 weeks of age when 
maintained in a CV environment, but not in GF conditions.59 
The clinical and histological characteristic of this inflam-
mation bears striking resemblance to human UC, including 
crypt abscess, ulcerations, and loss of goblet cells.59 Of note, 
GF-reared IL-2 KO mice showed signs of other non-UC phe-
notypes such as disturbances in bone marrow hematopoietic 
cells, lymphocytic hyperplasia, hemolytic anemia, and gen-
eralized autoimmunity, but not colitis. SPF-maintained mice 
begin to show signs of colonic inflammation only at 17–20 
weeks of age, and heightened T-cell and B-cell activation were 
found to mediate the colitis.59 These T cells are presumably 
activated through altered antigen presentation by DCs. In 
IL-2 KO mice, colonic DCs increase four- to five-fold under 
inflammatory conditions and localize within the T- and B-cell 
aggregates, expressing high levels of major histocompatibil-
ity complex class II, CD80, CD86, CD40, CD205, and C-C 
chemokine receptor type 5 molecules.60 These changes in DC 
phenotype may be induced by certain colitogenic bacteria or 
antigens. It was shown that Bacteroides vulgatus mpk mono-
colonized IL-2 KO mice do not manifest colitis but instead 
exert protective effect, unlike E. coli mpk monocolonized 
IL-2 KO mice that develop disease.61,62 Bacteroides vulgatus 
mpk-infected IL-2 KO mice increase IL-6 expression and 
semimaturation of LP DCs.62 It was reported that intestinal 
bacterial flora and endogenous antigens, but not environmental 
antigens, are the main contributors affecting SPF-associated 
colitis phenotype in this murine model.63
Specific targets have been identified to control the severity of 
colitis in IL-2 KO mice. It was noted that 2,4,6-trinitrophenol–
ovalbumin-immunized IL-2 KO mice displayed much more 
severe intestinal inflammation as compared with untreated 
mice. In contrast, mice administrated monoclonal Abs against 
the αEβ7 integrin together with 2,4,6-trinitrophenol– ovalbumin 
immunization demonstrated attenuated disease associated with 
a reduction in CD4+ cells and IFNγ production in the LP.64 In 
addition, treating 8-week-old IL-2 KO mice with green tea 
polyphenol extract in the drinking water reduced IFNγ and 
TNFα production after 1 week of treatment and displayed 
further improvement in the general histological scores of the 
spontaneous colitis after 6 weeks.65
Gαi2 KO mice
Guanine nucleotide-binding protein G(i) subunit α-2 (Gαi2) 
KO mice exhibit distinct lethal diffuse colitis phenotype 
within 5–7 weeks of age, associated with clinical and 
histopathological features resembling UC.66 These include 
colonic thickening, lymphocyte and neutrophilic infiltrations, 
crypt and goblet loss, and crypt abscesses. Cell analysis also 
showed a marked increase in memory CD44high, CD45RBlow, 
and CD62Llow CD4+ T cells in LP.67 Transfer of Gαi2 KO 
splenic CD3+ T cells, but not MLN CD3+ T cells, into 
immunodeficient mice causes severe colitis.68 B cells within 
the hematopoietic compartment appear to be an important 
regulatory factor in controlling the colitis phenotype in 
Gαi2 KO mice, as indicated by a reduction in LPS-induced 
proliferation and IL-10 production.69 Indeed, cell transfer of 
B cells isolated from wild-type MLNs can protect Gαi2 KO 
mice from colitis.
Testing of therapeutic agents in Gαi2 KO mice has 
shown positive results in ameliorating colitis. Intraperitoneal 
injection of the acellular Bordetella pertussis vaccine into 
Gαi2 KO mice demonstrated an increase in regulatory IL-10 
production in the intestine, accompanied by a significant 
reduction in colitis.70 Excessive proliferation of CD4+ T cells 
was controlled upon treatment, along with an increase in 
apoptosis of activated Th1-type CD4+ T cells. Ex vivo cul-
tures of colons obtained from Gαi2 KO mice respond to the 
anti-inflammatory agent methyl-prednisolone in a similar 
manner as colons from mice that had been orally treated with 
the same drug, as determined by inflammatory-associated 
gene expression.71 Hence, colonic culture systems, rather 
than in vivo testing, can be utilized to validate future IBD 
therapies.
Comparative evaluation  
of various animal ulcerative colitis  
models in drug development
With the current spectrum of animal models available to 
study UC, together with the explosive information of the 
underlying molecular pathogenesis of the disease, these 
resources can be carefully leveraged to determine the best 
approaches to design therapeutic drug targets to combat the 
disease (Figure 3).
The most obvious dogma is to start testing using lower 
organism models, including Caenorhabditis elegans, 
drosophila, and zebrafish, that provide a convenient and 
fast approach to doing large-scale screenings of both drugs 
and genetic targets (see review by Lin and Hackam72). 
These lower organisms are ideal subjects to study microbial 
response, as well as understanding the genetics of signal-
ing pathway or intestinal physiology. Upon identifying 
drug candidates or genetic targets from pilot tests in lower 
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organisms, further precise investigation can be performed 
using mouse models. It is important to first identify the 
most appropriate model that best represents the component 
in which the drug is exerting its effect: T-cell-mediated 
UC (IL-7 transgene, TCRα KO, WASP KO, Gαi2 KO, and 
IL-2 KO mice), B-cell biology (Gαi2 KO mice), intestinal 
barrier dysfunction (Mdr1a KO mice), and signaling path-
way dysregulation (Gαi2 KO mice). Of note, the condition 
of animal husbandry and the cleanliness of the mouse 
facility (eg, GF, SPF, or CV) will have robust effects on 
the results, including the penetrance and severity of colitis 
in the mice.
If the drug candidate does not pertain to any specific 
pathway/process, chemically induced colitis mice may be a 
good approach. The advantage of using these methods, as 
compared with spontaneous models, is the ease of controlling 
the chemical dosage, which affects the extent and severity 
of colitis. This is particularly useful when multiple doses of 
the drug are to be administered. In addition, the duration 
of the induction is also highly controllable, hence allowing 
one to dissect between onset, acute, and recovery phases of 
the colitis.
When the desired outcome of the new candidate drug/
therapy is observed in the rodent colitis models, further 
investigation can be extended to larger animal models, such 
as porcine or sheep.72 The morphology and physiology of pig 
intestine share a high degree of similarity to those of humans 
and thus may better reflect responses in patients. Finally, 
positive findings of a novel therapeutic agent in preclinical 
testing in animal models can then be extended into a Phase 
I clinical trial for human UC patients.
Role of animal models in the  
development of alternative  
and emerging ulcerative  
colitis treatments
Current drug treatment for UC patients includes 5 amin-
osalicylic acid (5-ASA), corticosteroids, thiopurines, and 
anti-TNFα Abs. Except for 5-ASA, the mechanisms of action 
of which is not entirely clear, these therapies aim to exert 
immunosuppression to control the extent of inflammation. 
However, long-term efficacy is achieved only in approxi-
mately one-third of the patients with moderate to severe 
T cell
TCRα−/− mice
WASP−/− mice
Mdr1a−/− mice
B cell
Gαi2−/− mice
Immunoregulatory
IL-2−/− mice
IL-7 Tg mice
WASP−/− mice
Epithelial signaling pathway
C. elegans
Drosophila
Bacterial virulence factors
Salmonella infection
AIEC infection
Host-microbial interaction
Salmonella infection
AIEC infection
Chemically induced colitis
(DSS, oxazolone)
Environmental/bacterial flora
C. elegans
Zebrafish
Mouse (husbandry)
Epithelial barrier
DSS
Oxazolone
Acetic acid
Sulfhydryl inhibitors
Mdr1a−/− mice
Figure 3 Ulcerative colitis (UC) models that address the specific framework of disease pathology. Invertebrate (eg, Caenorhabditis elegans, drosophila) and vertebrate 
(eg, zebrafish, mouse) models have their respective advantages in the study of UC pathogenesis. Different models can be utilized and carefully chosen to more appropriately 
address particular questions, mainly altered enteric microbial membership, intestinal epithelial dysregulation, and aberrant immune responses.
Abbreviations: AieC, adherent–invasive Escherichia coli; DSS, dextran sulfate sodium; Gαi2, guanine nucleotide-binding protein G(i) subunit α-2; iL, interleukin; Mdr1a, multiple 
drug resistance 1a; TCR, T-cell receptor; Tg, transgenic; wASP, wiskott–Aldrich syndrome protein.
Drug Design, Development and Therapy 2013:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1349
Animal models of UC
disease and is accompanied and restricted by adverse effects, 
including risks of infections, lymphoma, and nonmelanoma 
skin cancer. Animal models have provided a platform for 
insights into emerging therapies that hopefully will be more 
efficacious and/or safe (Figure 4).
Antibodies targeting immune cell 
trafficking to the gut
A potential target to treat chronic intestinal inflammation 
is to intervene with the process of immune cell recruitment 
and infiltration into the intestine. Leukocytes rapidly circu-
late through the microvasculature unless there is a specific 
signal for cells to exit the circulation and penetrate target 
organs. This process requires signaling between integrins 
on the endothelial surface (called adhesion molecules) and 
their receptors on the leukocyte surface membrane. Pertinent 
to the gut, mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) is expressed only in the intestinal tract and 
its associated lymphoid tissue and is recognized by its 
receptor α4β7 on the leukocyte surface, whereas vascular 
cell adhesion molecule-1 is expressed on endothelial cells 
in other organs besides the intestinal mucosa and functions 
as a ligand for both receptors α4β7 and α4β1.73 Studies in 
animal models from more than a decade ago demonstrated 
the efficacy of inhibiting these signals in the treatment of 
chronic colitis. Podolsky et al74 and Hesterberg et al75 dem-
onstrated attenuation of acute colitis in cotton-top tamarins 
by administration of anti-α4 monoclonal antibody and anti-
α4β7 monoclonal antibody, respectively. At the same time, 
Picarella et al76 demonstrated the efficacy of Abs to β7 and 
to MAdCAM-1 in ameliorating colitis induced by transfer of 
CD4+CD45RBhi cells into lymphopenic mice. These preclini-
cal studies demonstrated the proof of concept that interfering 
with leukocyte trafficking to the intestine could be effective 
colitis treatment.
Given that expression of mucosal adhesion molecules 
MAdCAM-1, intercellular adhesion molecule-1, and vascular 
cell adhesion molecule-1 have been described in mucosal 
tissues from patients with either CD or UC, Abs to these 
molecules and their corresponding receptors were deemed 
favorable targets as novel therapies for IBD (Figure 5).77 
Natalizumab, a monoclonal antibody to α4 integrin, was 
Current standard treatment:
Corticosteroids, anti-TNFα Abs, Thiopurines
Potential emerging standard treatment:
Potential emerging alternative treatment:
Immune trafficking antibodies, cytokine signaling inhibitors
Bone marrow transplant, Helminth infection, stem cell therapy
Current alternative treatment:
Probiotics, antibiotics
Potential emerging alternative treatment:
Fecal microbial transplant
Current standard treatment:
5-ASA
Potential emerging alternative treatment:
Stem cell therapy
Restoration of enteric microbial flora
Epithelial health
Immunoregulation
Figure 4 Current and emerging drug/therapy for ulcerative colitis (UC) treatment. Current treatments of UC mainly function by immunosuppression. Emerging therapies 
of UC have potential to target three major layers of UC dysfunction, including restoration of normal intestinal microbial flora, promotion of epithelial health (restitution of 
epithelium), and suppression of immunological cell trafficking and activation, with potentially fewer side effects compared with current available treatments.
Abbreviations: 5-ASA, 5-aminosalicylic acid; Abs, antibodies; TNF, tumor necrosis factor.
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approved in 2008 by the US Food and Drug Administration 
(FDA) for severe, refractory CD after efficacy was docu-
mented.78,79 However, its use is highly limited due to the risk 
of progressive multifocal leukoencephalopathy, a potentially 
fatal demyelinating disease, given its interference with leuko-
cyte homing to the central nervous system through blockade 
of α4β1 signaling. Therefore, targeting α4β7 more specifi-
cally with vedolizumab (aka MLN02 and MLN0002) should 
theoretically avoid this risk. Data from Phase III clinical trials 
demonstrate benefit in inducing and maintaining response in 
patients with moderately to severely active CD or UC, with no 
case of progressive multifocal leukoencephalopathy reported 
thus far, despite more than 2,000 patients having received 
at least one dose of vedolizumab in a clinical trial setting.80 
At this moment, vedolizumab is awaiting FDA approval for 
both CD and UC.
Similar to the idea of blocking α4β7, an antibody against 
β7 and other specific inhibitors of trafficking to the gut are 
also actively being investigated, given encouraging results 
from animal studies. Based on the effect of β7 antibody 
on the murine colitis model of CD45RBhi transfer and the 
positive results from a Phase I study showing safety and a 
hint of efficacy, etrolizumab (aka rhuMABβ7) is undergoing 
Phase II testing for UC.76,81 Similarly, MAdCAM-1 mono-
clonal antibody PF-00547,659 demonstrated some efficacy 
for UC.82 Even though alicaforsen (ISIS 2302), an inhibi-
tor of intercellular adhesion molecule-1 (ICAM-1), was 
not obviously efficacious in CD, an enema formulation of 
an ICAM-1 inhibitor was found to be comparable with 
mesalamine (a commonly used medication) in efficacy for 
left-sided UC.83–85 Overall, these results establish inhibitors 
of gut-homing molecules to be effective in treating IBD, as 
was seen in animal models in the 1990s.
Inhibition of cytokine signaling
Instead of inhibiting particular cytokines, one successful 
method of treatment has been through blocking the signal-
ing pathway shared by multiple cytokines. Receptors within 
the IL-2R family (IL-2, IL-7, IL-9, IL-15, and IL-21) com-
prise two subunits, a shared common gamma subunit, and 
a second subunit that is specific to the particular cytokine.86 
The common gamma subunit signals through activation of 
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Figure 5 Blocking of immune cell trafficking to the colon. Upregulation of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on intestinal vascular cells and 
expression of integrins (eg, α4β7) on lymphocytes promote interaction and adhesion of lymphocytes onto the intestinal endothelium and subsequent extravasation into 
colonic tissues. Blocking MAdCAM-1 or α4β7 using specific antibodies disrupts this interaction and control of colitis severity.
Abbreviation: ieCs, intestinal epithelial cells.
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the protein tyrosine kinase Janus kinase 3 (Jak3), which 
is expressed solely in immune cells. Jak molecules then 
transduce the cytokine signal through different isoforms of 
signal transducer and activator of transcription (STAT), lead-
ing to downstream gene activation. As STAT3 activation is 
important in IL-6-mediated T-cell proliferation and in T-cell-
mediated colitis, given STAT3 KO CD4+CD45RBhi cells are 
unable to induce colitis when transferred into a lymphopenic 
host, and given STAT3 variants have been associated with 
increased risks of UC, a selective inhibitor of Jak3 represents 
a promising novel therapeutic option for colitis without other 
unwanted effects.6,87 Preclinical data are limited to one study 
demonstrating efficacy of intraperitoneal injection of Janex-
1, an inhibitor of Jak3, in attenuating TNBS-induced colitis, 
but given known benefits in transplant rejection, rheumatoid 
arthritis, and psoriasis, it was tried on UC.88 Phase II data 
revealed efficacy of tofacitinib, an oral Jak3 inhibitor, in 
inducing response and remission in moderately to severely 
active UC in a dose-dependent manner.89 Phase III clinical 
trials are undergoing, with hopes of FDA approval in the near 
future. If confirmed to be effective, tofacitinib would become 
the only nonsteroidal oral treatment to induce remission for 
moderately to severely active UC.
Appendectomy
Appendectomy, especially during childhood, is inversely 
associated with the risk of UC development and has been 
increasingly supported by both clinical and experimental 
studies. One of the earliest observations was reported 
in 1987 by Gilat et al90 in a study in search of childhood 
causal factors of IBD. Subsequently, a large Swedish cohort 
analyzing 212,963 patients (with matched controls) who 
had undergone appendectomy before the age of 50 years 
was followed for development of UC.91 It was found that 
inflammatory-associated appendectomy (eg, appendicitis 
or lymphadenitis), but not nonspecific abdominal pain, cor-
related with the lower risk of subsequent UC. Therefore, 
inflammation of the appendix preceding appendectomy, 
rather than appendectomy itself per se, appears to confer the 
protection against UC. Importantly, this correlation is specific 
to patients who have undergone appendectomy before the 
age of 20 years.
One of the earliest reports on the effect of appendectomy 
on experimental colitis in animal models was reported by 
Mizoguchi et al92 using the TCRα KO mice. When appen-
dectomy was performed in young (3–5 weeks) TCRα KO 
mice, only 3.3% developed spontaneous intestinal inflamma-
tion after 6–7 months, with reduced MLN cell population, 
whereas up to 80% of sham-operated TCRα KO mice 
developed colitis during the same period. The structure of 
the appendix lymphoid follicle is highly similar to intestinal 
PP, and cellular proliferation rate in the appendix lymphoid 
follicle is twice that in the PP.92 Thus, it appears that appendix-
 associated/derived lymphocytes may hold key roles in UC 
development.
In a separate report, 7-day treatment with 2.5% DSS of 
mice that underwent appendectomy showed delayed onset 
and course of colitis development as compared with sham-
operated mice.93 This was also accompanied with lower 
colonic damage scores and a reduction in ulcerated mucosal 
surface area. Interestingly, splenectomy did not show any 
benefits in DSS-induced colitis. Thus, although spleen 
enlargement is a frequent phenotype during DSS treatment, 
the fact that splenectomy did not confer protection suggests 
that this enlargement is a consequence, not a cause, of DSS-
induced colitis.
Finally, the protective effect of appendectomy was also 
nicely demonstrated in a T-cell transfer colitis experiment.94 
Fluorescence-labeled colitis-inducing CD62L+ CD4+ cells 
that were transferred into immunodeficient severe com-
bined immunodeficiency (SCID) mice were found to have a 
3.5-fold preferential homing toward the appendix than the 
colon and to express high levels of α4β7 adhesion molecule 
costimulatory molecule CD154. Therefore, with the help of 
various UC animal models, detailed characterization of the 
components within the appendix may further shed light on 
the pathophysiology underlying UC development to facilitate 
future therapeutic intervention attempts.
Helminth therapy
Increasing reports on both colitis mouse models as well as 
human UC clinical trials demonstrate that helminth infec-
tion provides beneficial effects on UC. Studies on helminth 
infection in UC mouse models have provided mechanistic 
insights into how the nematode induces tolerogenic DCs that 
can block colitis development and regulate T-cell responses.95 
In addition to an immunoregulatory effect on adaptive 
immunity, evidence has supported that helminth infection 
can promote IL-22-mediated mucosal barrier regulation and 
gut microbiota to improve intestinal inflammation.96
The identification of these specific helminth factors can 
provide alternatively effective and safe treatment. It was 
demonstrated that injection of the hookworm Ancylostoma 
caninum-derived excretory/secretory factors can induce 
IL-4+ IL-10+ CD4+ T-cell response and ameliorate DSS-
induced colitis in mice.97 To specifically determine the precise 
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factors that have such protective effect, Cantacessi et al98 
have characterized the transcriptome of Trichuris suis using 
next-generation sequencing. Recently, Du et al99 reported that 
subcutaneous injection into colitic mice with a recombinant 
of a helminth excretory–secretory protein called Trichinella 
spiralis 53 kDa protein reduces disease activity index and 
macroscopic and microscopic inflammation score. Testing in 
UC animal models will hopefully further identify therapeuti-
cally effective products among helminth-derived factors to 
broaden clinical treatment options.
Amidst the success of helminth therapy in mouse models 
and human clinical trials, several reports have provided dif-
ferent effects and perspectives. Recently, Bager et al100 dem-
onstrated in population-based cohort studies that infection of 
the helminth pinworm that causes enterobiasis does not lower 
the risk of UC. They suggested that, in contrast to pinworms, 
hookworms or schistosomes thrive in tropical countries, 
and thus the higher rates of chronic inflammatory disease, 
including UC, in nontropical regions may be an effect of the 
absence of tropical helminth. In addition, Wang et al101 have 
also reported an exacerbation of disease by the tapeworm 
Hymenolepis diminuta infected into oxazolone-induced 
colitic mice through IL-5-mediated immune responses. These 
data suggest that perhaps not all helminth are protective, and 
careful characterization of helminth-based therapy in mouse 
models is critical to identify the efficacy and safety aspects 
before proceeding to human clinical trials.102
Stem cell-based therapy
Pluripotent cell-based therapy for CD is in Phase I trials, 
which may provide informative insights in the treatments 
for UC patients as well.103 Colitic IL-10 KO mice that 
were injected with nondifferentiated embryonic stem cells 
tagged with yellow fluorescence protein showed homing 
in the colon, small intestine, liver, and thymus tissues, but 
not in the spleen or bone marrow, associated with improved 
colitis inflammatory scores upon transplantation.104 In addi-
tion, transplantation of IECs from in vivo predifferentiated 
embryonic stem cells into mice was also found effective in 
reducing inflammation and in restoration of immune balance. 
A similar test using IL-10 KO mice with active colitis was 
performed through intracolonic infusion of colonic stem 
cells, which showed an ameliorative effect on colitis.105 The 
authors therefore suggested that colonic stem cells provide 
a safer option for colitis treatment, as compared with those 
of systemic stem cell administration.
Bone-marrow derived cells (BMDCs) have also been 
demonstrated to control the extent of inflammation when 
transplanted into colitic mice. Lethally irradiated DSS-
induced colitic mice transplanted with BMDCs from green 
fluorescence protein (GFP) Tg mice showed the presence of 
GFP in vimentin+ colonic interstitial cells, but not Ki-67+-
proliferating cells, cytokeratin+ epithelial cells, or CD31+ 
endothelial cells.106 The transplanted GFP BMDCs frequently 
transdifferentiated into subepithelial myofibroblasts and 
fibroblasts that reside in the colonic subepithelium even after 
recovery. To fully correct the immunodysregulation in colitis, 
it was demonstrated that total body irradiation followed by 
transplantation of BMDCs is more effective in ameliorating 
colitis in mice.107
Systemic infusion of mesenchymal stem cells (MSCs) 
in DSS-induced colitis mice also ameliorated colitis, 
characterized by downregulation of TNFα and IL-1β.108 
Mechanistically, MSC systemic infusion induced transient 
T-cell apoptosis via the Fas/Fas ligand-dependent apoptotic 
pathway.109 The apoptotic T cells then trigger macrophages 
to produce high levels of transforming growth factor-β, 
resulting in the upregulation of CD4+CD25+Foxp3+ Treg 
production and, eventually, enhanced immune tolerance. 
Colitic rats showed the presence of the transplanted MSCs 
only in the LP.110 In addition, topical implantation, rather than 
systemic transplantation, of MSCs into the chemically injured 
intestinal area is sufficient to promote the healing process.111 
This success utilizing stem cell therapy in animal models is 
promising as an emerging therapy for human disease and 
has been studied in clinical trials.103 Further investigation in 
animal models will aid in determining the long-term fate of 
the engrafted stem cells, to ensure long-term safety of this 
mode of UC therapy.
Fecal microbiota transplant
Aiming to balance the dysregulated intestinal microbiome 
has been attempted through probiotics treatment, with some 
degree of success in clinical and animal studies.112 However, 
the outcome is nevertheless variable and modest, and so 
probiotics are considered supplementary and not substitutes 
for conventional therapy. Therefore, the potential of fecal 
microbiota transplantation (FMT) to regulate the homeostasis 
of the abnormal intestinal microbiota now poses an attractive 
alternative method for UC treatment.
One of the pioneering investigations of FMT as a UC 
treatment was reported by Bennet and Brinkman,113 where 
Bennet himself was suffering from UC and self-experimented 
with FMT, reporting improvements after 3 months with 
resolution of symptoms after 6 months. Although it is 
perceived that the normal flora present in FMT donors can 
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restore the normal balance in dysregulated microbial flora 
in IBD patients, the proper mechanism behind the FMT 
effect is currently still obscure. Mice that were deficient 
in nucleotide-binding oligomerization domain 2 and given 
FMT showed a reduced disease risk and long-term changes 
in microbiota compositions.114 Conversely, wild-type mice 
that were transplanted with the dysregulated fecal microbiota 
derived from nucleotide-binding oligomerization domain 
2 KO mice showed increased disease risk, suggesting the 
presence of particular microbial subsets that may be protec-
tive or colitogenic.
Recent survey results have revealed that the majority of 
UC patients show keen interest in considering FMT in their 
treatment regimen.115 With the emerging technology and 
maturation of humanized mouse models, mouse models of 
UC will serve as a valuable tool to elucidate the mechanism 
behind FMT beneficial effects, as well as to define proper 
safety issues and long-term effects.
Herbal and plant extracts
The therapeutic effects of herbal or plant extracts have been 
exploited for centuries, and identifying and characterizing 
these components can provide alternative treatment options 
for UC patients. These include both Western-derived herbs as 
well as traditional Chinese medicine. Many of the reported 
randomized clinical trials compared the efficacy of these 
alternative agents with that of standard treatments (ie, 5-ASA, 
sulfasalazine, and steroids) or placebo. A literature review 
reported that the number of subjects who have undergone 
clinical trials using a herbal treatment for UC from 1947 to 
2013 ranges from 14 to 224 subjects, with treatment duration 
lasting for 4–12 weeks.116 No major adverse reactions, other 
than minor side effects, including nausea, constipation, and 
flatulence, were reported to be associated with these different 
herbal treatments.116 The major herb/plant extracts that have 
been shown to have potential benefit for UC include aloe vera, 
Boswellia serrata, butyrate, licorice, slippery elm, tormential 
extracts, wheat grass, curcumin, bromelain, and psyllium (see 
review by Ke et al117). One main aim of the treatment is to 
induce remission of UC, whereby aloe vera, wheat grass, and 
HMPL-004 (Andrographis paniculata extract) appear to have 
some efficacy when compared with placebo controls.118–120 
Another major goal of herb/plant extract therapy is to main-
tain remission in UC, in which curcumin, myrrh, chamomile 
extracts, and coffee charcoal treatment in patients results in a 
relapsed rate that is comparable with 5-ASA-treated patients 
in randomized clinical trial reports.121,122 However, caution 
needs to be taken in interpreting these observations, given 
many of these studies were done on patients with only mild 
disease, treatment effects were not rigorously tested with 
objective endpoints in all studies, and long-term safety and 
efficacy are not known.
Given some hint of efficacy, it is important to understand 
the underlying mechanisms behind the potential therapeutic 
effects of these herbs and plant extracts by using UC animal 
models. For instance, A. paniculata extract (HMPL-004) 
has been demonstrated to reduce splenic CD4+ T cells as 
well as inhibit CD4+ T-cell proliferation and differentiation 
into Th1/Th17 effector cells in a murine CD45RBhi cell 
transfer model.123 In Mdr1a KO colitic mice, reduction of 
colitis histological signs by curcumin treatment is associated 
with upregulation of xenobiotic metabolism and also down-
regulation of proinflammatory pathways.55 These studies 
provide further in vivo mechanistic understanding of how 
each individual herb/plant extract may work, facilitating the 
choice of the most appropriate herbal treatment for defined 
groups of patients.
Conclusion
Animal models have become indispensable tools to study 
mechanisms and treatments of diseases. Insights learned from 
such models allow us to design novel therapeutic strategies 
and to define, in a preclinical setting, the safety and efficacy 
of such novel treatments before human clinical trials. The 
fact that there are currently numerous models available also 
indicates that no single model is perfect, and it is therefore 
essential to define the specific question in mind, in order to 
identify the ideal model for study.
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